ERG11 mutations and expression of resistance genes in fluconazole-resistant Candida albicans isolates
- 553 Downloads
Azole resistance in the pathogenic yeast Candida albicans poses significant challenges for its antibiotic treatment. The conformational change of the target enzyme 14 alpha-demethylase (Erg11p) due to ERG11 gene mutations is one of the mechanisms resulting in the azole resistance. ERG11 of 23 isolates (8 susceptible and 15 resistant) and 6 standard strains of Candida albicans were amplified and sequenced. Nineteen missense mutations were detected. Two mutations, G487T (A114S) and T916C (Y257H), coexisted exclusively in 14 fluconazole-resistant isolates. To identify the resistance mechanisms in the isolates with G487T and T916C mutations, we compared the expression of 5 resistance-related genes in the 14 azole-resistant isolates with those in the susceptible type strain ATCC 10231, Saccharomyces cerevisiae AD/CDR1 and AD/CDR2. The tested values of mRNA transcription of CDR1 and CDR2 were higher than that of control strain, while the semi-quantified Cdr1p values were not higher in all of the 14 resistant isolates. And the data analyzed with t test suggest that both of the differences are significant (P < 0.0005) when the resistant isolates are considered as a whole. Cdr2p was up-regulated in 5 isolates, and down-regulated or even undetectable in the remaining 9 isolates. The transcription of ERG11, MDR1, and FLU1 varied in these isolates. These data suggested that overexpression of the five genes might not be the reason of resistance in the 14 isolates with G487T and T916C, especially in the 5 isolates (GZ09, GZ15, GZ16, GZ58, and 4263) in which neither translation of Cdr1p/Cdr2p nor transcription of ERG11, MDR1, or FLU1 was detected up-regulated. The results suggest that Erg11p conformational change due to the point mutations is most likely responsible for the azole resistance in these isolates.
KeywordsCandida albicans Drug resistance ERG11 Genes, MDR Mutation
This study was funded by the National Science Foundation of China (No. 30901294), the Shandong Provincial Science and Technology Project Fundation (No. 2009GG2NC02004), and the Shandong Provincial Natural Science Foundation, China (No. ZR2011HQ005). We thank Prof. John E. Bennett (National Institutes of Health, USA), Prof. Ann R. Holmes (Otago University, New Zealand), Prof. Liyan Xi (Sun Yat-sen University, China), Prof. Ruoyu Li (Peking University, China), Prof. Yongnian Shen (Chinese Cultural Collection Commission for Microbiology, China) for their kindly supply of isolates, or type strains, and Prof. Dominique Sanglard (University of Lausanne, Switzerland) for his anti-Cdr1p antibody as a gift.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Clinical and Laboratory Standards Institute (2008) M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PAGoogle Scholar
- Goldman GH, da Silva Ferreira ME, dos Reis Marques E, Savoldi M, Perlin D, Park S, Godoy Martinez PC, Goldman MH, Colombo AL (2004) Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 50:25–32CrossRefPubMedGoogle Scholar
- Holmes AR, Lin YH, Niimi K, Lamping E, Keniya M, Niimi M, Tanabe K, Monk BC, Cannon RD (2008) ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical Isolates. Antimicrob Agents Chemother 52:3851–3862PubMedCentralCrossRefPubMedGoogle Scholar
- Jiang WS, Tan SS, Jiang GY, Chen QX (2006) Synergistic effect of terbinafine combined with fluconazole or itroconazole on stable fluconazole-resistant Candida albicans induced by fluconazole in vitro. Chin J Microbiol Immunol 26:360–364Google Scholar
- Long F, Zhang YX, Lan HK, Wang YY, Zhu DM, Ren DM (2002) The point mutation of cytochrome P-450 lanosterol 14-α demethylase ERG11 gene in Fluconazole-resistant Candida albicans. Chin J Infect Dis 20:211–214Google Scholar
- Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL(2010) A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob Agents Chemother 54:3578–3583. Published online 2010 Jun 14. doi: 10.1128/AAC.00303-10
- Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D, Patterson TF (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole-resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45:2676–2684PubMedCentralCrossRefPubMedGoogle Scholar
- Sanglard D, Ischer F, Koymans L, Bille J (1998) Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42:241–253PubMedCentralCrossRefPubMedGoogle Scholar